20 June 2013
Keywords: eisai, regains, rights, antifungal, b-ms, japan, terminated
Article | 08 November 2004
Japan's Eisai has terminated a licensing agreement with US drug major Bristol-Myers Squibb for its antifungal agent, ravuconazole. The
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
8 November 2004
1 November 2004
19 June 2013
© 2013 thepharmaletter.com